Cornerstone Advisory’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $390K | Buy |
6,436
+319
| +5% | +$18.6K | 0.04% | 187 |
|
|
2025
Q4 | $330K | Sell |
6,117
-82
| -1% | -$3.94K | 0.03% | 192 |
|
|
2025
Q3 | $280K | Buy |
6,199
+32
| +0.5% | +$1.49K | 0.03% | 200 |
|
|
2025
Q2 | $285K | Sell |
6,167
-1,510
| -20% | -$74.1K | 0.03% | 192 |
|
|
2025
Q1 | $365K | Buy |
7,677
+182
| +2% | +$10.6K | 0.04% | 166 |
|
|
2024
Q4 | $404K | Buy |
7,495
+852
| +13% | +$47.6K | 0.05% | 159 |
|
|
2024
Q3 | $344K | Sell |
6,643
-1,381
| -17% | -$64.8K | 0.05% | 167 |
|
|
2024
Q2 | $333K | Sell |
8,024
-3,367
| -30% | -$151K | 0.05% | 159 |
|
|
2024
Q1 | $618K | Buy |
11,391
+626
| +6% | +$31.9K | 0.09% | 125 |
|
|
2023
Q4 | $552K | Sell |
10,765
-3,024
| -22% | -$159K | 0.09% | 128 |
|
|
2023
Q3 | $800K | Sell |
13,789
-458
| -3% | -$28.1K | 0.14% | 94 |
|
|
2023
Q2 | $911K | Sell |
14,247
-392
| -3% | -$26.3K | 0.16% | 88 |
|
|
2023
Q1 | $1.01M | Sell |
14,639
-787
| -5% | -$55.5K | 0.18% | 82 |
|
|
2022
Q4 | $1.11M | Buy |
15,426
+1,120
| +8% | +$84.5K | 0.22% | 71 |
|
|
2022
Q3 | $1.02M | Buy |
14,306
+288
| +2% | +$20.9K | 0.23% | 69 |
|
|
2022
Q2 | $1.08M | Sell |
14,018
-6,211
| -31% | -$473K | 0.25% | 66 |
|
|
2022
Q1 | $1.48M | Buy |
20,229
+4,438
| +28% | +$298K | 0.23% | 76 |
|
|
2021
Q4 | $984K | Sell |
15,791
-3,017
| -16% | -$177K | 0.14% | 110 |
|
|
2021
Q3 | $1.11M | Buy |
18,808
+8
| +0% | +$527 | 0.18% | 90 |
|
|
2021
Q2 | $1.26M | Buy |
18,800
+4,142
| +28% | +$270K | 0.21% | 83 |
|
|
2021
Q1 | $926K | Buy |
14,658
+1,388
| +10% | +$86.4K | 0.18% | 100 |
|
|
2020
Q4 | $824K | Buy |
13,270
+6
| +0% | +$369 | 0.17% | 107 |
|
|
2020
Q3 | $799K | Buy |
13,264
+3,923
| +42% | +$236K | 0.19% | 97 |
|
|
2020
Q2 | $549K | Buy |
9,341
+503
| +6% | +$30.1K | 0.14% | 111 |
|
|
2020
Q1 | $493K | Buy |
8,838
+2,389
| +37% | +$146K | 0.15% | 92 |
|
|
2019
Q4 | $414K | Sell |
6,449
-427
| -6% | -$24.5K | 0.09% | 123 |
|
|
2019
Q3 | $349K | Sell |
6,876
-184
| -3% | -$8.65K | 0.08% | 128 |
|
|
2019
Q2 | $320K | Hold |
7,060
| – | – | 0.07% | 132 |
|
|
2019
Q1 | $337K | Sell |
7,060
-33
| -0.5% | -$1.64K | 0.07% | 128 |
|
|
2018
Q4 | $369K | Buy |
7,093
+1,137
| +19% | +$61.1K | 0.1% | 111 |
|
|
2018
Q3 | $370K | Buy |
5,956
+67
| +1% | +$3.98K | 0.11% | 111 |
|
|
2018
Q2 | $326K | Sell |
5,889
-184
| -3% | -$9.94K | 0.11% | 114 |
|
|
2018
Q1 | $384K | Buy |
6,073
+33
| +0.5% | +$2.12K | 0.14% | 102 |
|
|
2017
Q4 | $370K | Buy |
6,040
+117
| +2% | +$7.32K | 0.13% | 110 |
|
|
2017
Q3 | $378K | Sell |
5,923
-150
| -2% | -$8.76K | 0.13% | 110 |
|
|
2017
Q2 | $338K | Sell |
6,073
-632
| -9% | -$34.4K | 0.11% | 108 |
|
|
2017
Q1 | $365K | Sell |
6,705
-577
| -8% | -$31.6K | 0.18% | 77 |
|
|
2016
Q4 | $426K | Buy |
7,282
+432
| +6% | +$23.6K | 0.32% | 50 |
|
|
2016
Q3 | $369K | Buy |
6,850
+346
| +5% | +$22.2K | 0.3% | 53 |
|
|
2016
Q2 | $478K | Sell |
6,504
-26
| -0.4% | -$1.84K | 0.4% | 40 |
|
|
2016
Q1 | $417K | Buy |
6,530
+2
| +0% | +$126 | 0.36% | 45 |
|
|
2015
Q4 | $449K | Buy |
+6,528
| New | +$431K | 0.39% | 42 |
|
Other funds holding BMY
VCM
VPM
Cornerstone Advisory's BMY Position: Q1 2026 in Review
Cornerstone Advisory increased its Bristol-Myers Squibb (BMY) stake by 5.2% in Q1 2026, buying an estimated $18.6K and bringing the position to 6,436 shares worth $390K. The position accounts for 0.04% of the portfolio, ranked #187.
Cornerstone Advisory first reported a position in BMY in Q4 2015 and has held it in 42 quarters since. The position peaked at $1.48M in Q1 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Cornerstone Advisory held 6,436 shares of Bristol-Myers Squibb worth $390K as of Q1 2026.
- Cornerstone Advisory bought 319 Bristol-Myers Squibb shares in Q1 2026, an estimated $18.6K.
- Bristol-Myers Squibb made up 0.04% of Cornerstone Advisory's portfolio in Q1 2026, its #187 holding.
- Cornerstone Advisory first reported a position in Bristol-Myers Squibb in Q4 2015 and has held it in 42 quarters since.
- Cornerstone Advisory's Bristol-Myers Squibb position peaked at $1.48M in Q1 2022.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Cornerstone Advisory's 13F filing for Q1 2026, filed 4 May 2026.